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Project Objectives: 
The objectives of consulting for the University of Michigan Skin Bank (UMHSB) were 
the following: 
• To provide a financial analysis for the UMHSB operation 
• To compare UMHSB to industry norms and against burn care trends 
• To evaluate the UMHSB value to hospital operations 
• To suggest improvements should the UMHSB prove competitive within the industry 
• To recommend a profitable and strategically sound alternative should the UMHSB 
prove non-viable. 
Recommendations: 
1) Establish a "Center of Excellence" for burn care called "The University of 
Michigan Burn Resource Center". 
Establish a center of excellence to distribute a portfolio of leading edge bio-technical and 
.burn care products as well as Homograft (human cadaver skin). To accomplish this Burn 
and Trauma Center physicians will need to be trained by suppliers in the use of their 
products and will then provide consultation to regional healthcare facilities that also treat 
burn victims. Training will allow physicians to offer burn care expertise on the use of the 
portfolio of products supplied by The Burn Resource Center. Additionally, the UMHSB 
should offer professional training for a fee, whether at the University of Michigan 
Hospital or off sight. 
2) Require comprehensive funding from suppliers for new facilities, or changes to 
the existing facility, that are needed to convert the skin bank into The Burn 
Resource Center. 
Suppliers should provide financial resources to support the training programs. In 
addition to the costs for facility upgrades, suppliers should cover the initial physician 
training expenses and the pro-rated share of physicians' salaries (for their time spent 
training others). Profit should be generated through a combination of sources including 
supplier subsidy, outside physician training fees and retail profit margins from product 
sales. Additional profit should be generated by the UMH by charging a fee for suppliers 
that which to use The Burn Resource Center seal of approval in their marketing efforts. 
3) Inaugurate TransCyte as the first Burn Resource Center product with 
comprehensive training and support. 
Complement the product portfolio with Homograft procured externally from a low cost 
supplier. Use Smith and Nephew as a resource to develop the center. They have 
experience with Centers of Excellence in other product lines. 
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4) Phase out Homograft processing over a two-year period. Transition all 
customers to low cost, externally procured Homograft, which is distributed by 
the UMHSB. 
Take advantage of high volume purchases to gain better pricing. Process in-house only 
the tissue for Collagenesis with the intent to discontinue production at the end of the 
second year. Liquidate equipment that was used only to process tissue. 
5) Develop a formal process for approving products that will be offered and 
supported by The Burn Resource Center. 
A strict approval process is necessary to avoid favoritism and to build and maintain the 
credibility of The Burn Resource Center. If the approval process is not rigorous, the 
portfolio will eventually be filled with products from suppliers that are willing to 
subsidize The Burn Resource Center the most rather than by products that are truly 
advancements in burn care. 
Findings: 
Current skin bank operations encompass three activities: 
1. Skin processing, banking and internal/external distribution 
2. Microbiological testing to support the Burn and Trauma department 
3. Keratinocyte cell generation to fabricate and store tissue cultured from a patient's 
own skin. 
The 1998 revenues and costs for each function are stated below: 
Revenue 
Costs 













Of current Homograft sales, approximately 38% of revenues depend on sales to one 
customer, Collagenesis. This customer represents 82% of the total volume of external 
sales. Collagenesis requires a different, thicker type of skin tissue that is not used for 
surgical procedures. UMHSB is already a second source of supply and has been losing 
sales at a yearly rate of 8%. 
UMHSB is not price competitive with other suppliers of cadaver skin. The tissue 
banking industry has undergone extensive consolidation. To remain competitive other 
suppliers have combined the harvesting of higher margin tissue (cartilage, corneas, etc.) 
with the harvesting of skin tissue to achieve economies of scope. The harvesting teams 
are composed of surgical technicians, rather than doctors, who harvest tissue in a morgue 
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rather than an expensive operating room. The scale of operations and advantages of 
economies of scope cannot be surpassed by UMHSB unless significant investment is 
made. Even with significant investment it is unlikely that UMHSB can be cost 
competitive because it carries some of the hospitals significant overhead costs. 
Organizations such as the American Red Cross have specialized in harvesting tissue and 
their operations do not have the cost burden of hospital expenditures. 
Over the past three years the number of burn victims in the United States has declined. 
The severity of burns and the percent of body coverage however have increased 
dramatically. Resultantly, the treatment of burns is becoming more focused on the care 
of severe injuries for which grafting procedures are not viable because not enough 
healthy surface area remains for the graft to attach. 
Several new synthetic products threaten to replace Homograft, but as of yet are not used 
by the majority of physicians. Synthetic products are promising for several reasons. 
Firstly, they are significantly less likely to be rejected by the patient's auto immune 
system. Adoption of the synthetic graft means that only one application of the product is 
necessary. Homograft usually requires multiple applications every 8-10 days to prevent 
infections. Secondly, synthetic products are consistent from batch to batch so the doctor 
knows what to expect for every procedure. Thirdly, use of synthetic skin rather than 
Homograft reduces the potential for disease transmission significantly. Fourth, synthetic 
products have substantially longer shelf lives, exceeding Homograft by two times. 
Finally, synthetic skin is transported and stored more easily than Homograft. Approval is 
eminent for TransCyte to be stored at regular freezer temperatures rather than sub-zero 
environments this approval will significantly reduce the UMH storage costs. Several 
synthetic tissue products have been clinically tested at the University of Michigan 
Hospital with varied success, but only a few have been isolated as highly viable ~ one of 
these is TransCyte. 
The Burn and Trauma department of the University of Michigan Hospital enjoys an 
excellent reputation for setting the standard for burn and trauma care. The Burn and 
Trauma Center is unusual in the industry in that it earns a profit. Most other trauma 
departments are resource drains on hospitals and are therefore given little attention. As a 
result the care and reputation of these institutions suffer. The Burn and Trauma Center is 
a source of innovation in the care of patients and suppliers to this department view the 
relationship as highly valuable. 
Strategic Impact of Recommendations; 
The strategy of turning the skin bank into The Burn Resource Center has several positive 
repercussions, which include: 
Establishing the hospital as a resource center increases the prestige of the physicians 
and the hospital. Increased departmental prestige and physician prestige will draw 
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additional top doctors. Top physicians will increase the quality of the education at 
the UMH. High quality education will draw top pupils and top interns will again 
increase the prestige of UMH as a teaching hospital. The Burn Resource Center will 
generate a network of improvements that will vastly improve the quality of care 
delivered and the quality of the personnel. 
Offering consultative training to other facilities for a fee generates a new source of 
revenue. 
The skin bank business is declining and The Burn Resource Center will turn the 
operations into a thriving and profitable activity. 
Establishing a center of excellence for burn care has never been done before. 
Consequently, the activity will firmly establish the burn care capabilities of the 
University of Michigan Hospital as the de facto standard. 
Training of Dhvsicians by the suppliers of burn care products will ensure that the 
staff will have the most current capabilities. 
Suppliers of innovative products will seek out the University of Michigan Hospital 
before most other facilities because of the potential for Burn Resource Center 
approval and the resulting product credibility. 
The reputation of the Burn and Trauma center makes The Burn Resource Center 
approach viable and also difficult to imitate because potential imitators need first to 
build credibility and then they can attempt to form a center of excellence. 
The Burn Resource Center's prestige will lead to higher sales volumes. These higher 
sales volumes will increase the UMH power to negotiate discounts with suppliers. 
Potential problems: 
• High sales volumes and multiple product lines will necessitate an accurate costing 
and billing system. 
• As much as possible, the time dedicated to receiving and providing new product 
training must be evenly distributed among the entire cadre of physicians. Equitable 
distribution of responsibilities for this will reduce the possibility of certain individuals 
bearing most of the burden. 
• Suppliers need to pay for the training of each UMH physician. They also need to 
fully subsidize their travel and lodging expenses when they training physicians at 
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other locations. Also, suppliers need to offer incentives to physicians so they will be 
motivated to teach others. 
• Extended payment terms or consignment needs to be negotiated with the suppliers. 
The Burn Resource Center will carry significantly increased inventory in both 
quantity and variety of products. UMH should not be responsible for incurring the 
new inventory carrying costs. 
Conclusion and Comments: 
TransCyte, a promising product that has been tested extensively at the University of 
Michigan Hospital, has impressed physicians. For TransCyte to be broadly accepted in 
burn care units it needs to build credibility. Being approved for use by The Burn 
Resource Center will take the product a long way towards broader clinical acceptance. 
Most new clinical products require this sort of credibility building to become clinically 
accepted by physicians. Smith and Nephew, the maker of TransCyte, is willing to bring 
their resources to bear in support of the development of the center of excellence because 
they realize the value of UMH's approval. Other suppliers also realize that the approval 
of the highly prestigious University of Michigan Burn and Trauma department has real 
monetary value. As the prestige of The Burn Resource Center increases so will the value 
of approval. It is reasonable then for suppliers to pay a fee to advertise that their product 
has been accepted for use at The Burn Resource Center at the University of Michigan 
Hospital. The higher the prestige the more value the approval creates. 
Creating a center of excellence for burn care, as we have suggested, is an enormous 
opportunity not only to create new revenues but also to bolster prestige and 
institutionalize innovation. This endeavor is only possible because the Burn and Trauma 
department already is already highly reputable. Credibility and reputation are sources of 
significant competitive advantage and are extremely difficult to imitate. 
Suppliers will be of great assistance in the creation of this center. Smith and Nephew, for 
example, has assisted other institutions to develop centers of excellence that distribute 
other product lines. Other suppliers have also had similar experiences. Partnering with 
these suppliers must be viewed as a long-term relationship. Suppliers will need to be 
trusted to bring their innovations to The Burn Resource Center first; therefore close 
relationships with them are essential. 
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Summary of Cost Study 
Introduction: 
The skin banking operations at the University of Michigan Hospital, Trauma Burn center 
is becoming increasingly non-viable. In order to maintain the requisite services to 
patients, a new innovative approach to the skin bank process must be identified. This 
proposal describes our plan to establish closer relationships with suppliers which 
enhances patient service, profitability, and augments our relationships with community 
hospitals. 
Project Objectives: 
• Analyze current operations. 
• Develop a business plan. 
Financial Analysis: 
Homograft 
Total sq. ft. sold internally 
Total sq. ft. sold externally 
Revenues from internal sales 

































Total sq. ft. sold internally 
Total sq. ft. sold externally 
Revenues from direct internal sales 







































Total Net Profit [$388,642 $473,078 $394,798 $405,924 I $417364 
Current FTE employment levels and technical capabilities are sufficient to staff these 
new activities through 2003. 
Recommendations: 
. Convert the skin bank into a Burn Care Resource Center. 
• Ultimately carry a portfolio of bioengineered products 
• Suppliers pay capacity and distribution fee as well as volume rebate. 
• Partner with suppliers to develop an Education Center. 
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Analysis of Transcyte Proposal 
Homografi Revenues 
Total sq. ft. sold internally 
Total sq. ft. sold externally 
Total sq. ft. sold to Collagenesis 
Revenues from internal sales 
Revenues from external sales 
Revenues from sales to Collagenesis 
Total revenues 
Cost of goods sold (internal/external) 
Cost of goods sold (to Collagenesis) 
Gross profit 
































































Payroll (based on allocation of personnel) 
Utilities (allocation based on % of total tissue sold) 





















Other expenses (Depr., Insur., Disability, Retirement, Fica) 
Shipping/containers 
Dry ice (50 lbs per 5 cassettes @ $17.50) 
Operating Profit (before taxes) 



























Total cassettes sold internally 
Total cassettes sold externally 
Revenues from direct internal sales 
Revenues from direct external sales 
Rebate revenues 
Total revenues 
Cost of goods sold 
Gross profit 
















































Payroll (based on allocation of personnel) 
Utilities (allocation based on % of total tissue sold) 





















Other expenses (Depr., Insur., Disability, Retirement, Fica) 
Shipping/containers 
Dry Ice (50 lbs per 5 cassettes @ $17.50) 
Operating Profit (before taxes) 


























Total revenues (all tissues) 
Total cost of goods sold 
















| $316^92 [ $407,068 | $394,798 | $405,924 | $417j64 
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Revenue Projections 
Homograft Five Year Revenue Projections 
-Total revenues 
1999 2000 2001 2002 2003 
Year 
Transcyte Five Year Revenue Projections 
• Total revenues 
1999 2000 2001 2002 2003 
Year 
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Operating Income and Margins 
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TransCyte Proposal Assumptions 
1. 1999 external Homograft sales projections are based on actual sales volume achieved 
in the first five months of fiscal year 1999 annualized for 12 months. 
2. Actual sales volumes in the first five months of fiscal year 1999 show that sales to 
Collagenesis comprise 82% of all external Homograft sales. Our projections are 
based on this percentage. 
3. Calculations do not reflect inflation or expense increases over time. 
4. Smith & Nephew will sell Transcyte to the University of Michigan Hospital (UMH) 
on consignment. Therefore, UMH will not have to finance any Transcyte related 
inventory carrying costs other than utilities and facilities overhead. 
5. Inventory finance costs will be incurred for Homograft unless consignment is 
negotiated with the supplier. Financing cost of capital is not included in our 
projections. 
6. Revenues from distributing Transcyte will come from the discount off list price and 
cassette rebates only. Smith & Nephew will not pay any fee to UMH for 
endorsement of Transcyte. 
/. UMH doctors' fees for conducting training and assisting in procedures involving 
Transcyte at other hospitals are not included in our projections. Additionally, related 
incidental fees such as transportation, accommodation, and meals are also not 
included. 
8. Current man-hours consumed by Homograft related activities are 75% of total man-
hours used for both Homograft and Transcyte. 
9. Of the time expended on Homograft related activities, 40% is consumed by sales to 
Collagenesis, and 60% is consumed by internal and other external sales. 
10. Current man-hours consumed by Transcyte related activities are 25% of total man-
hours used for both Homograft and Transcyte. 
11. Time and personnel required when outsourcing Homograft tissue is one-fourth of that 
required when producing it in-house. 
12. The current skin bank facility is approximately 1,200 square feet. Homograft and 
TransCyte related activities will occupy one-third, or 400 square feet of the facility 
each. 
13. Space required for Homograft, Transcyte and microbiological activities each 
comprise one-third of the currently available space. This ratio will remain constant 
even though a product's percentage of total unit sales and volume sold will change. 
14. Facilities overhead is $25 per square foot. 
15. Homograft sales will decline 8% per annum due to reduction in burn victims and 
transfer to Transcyte. This estimate is based on historical trends. 
16. External sales of Homograft will initially increase due to a price reduction and 
broader customer base as a result of a wider product offering. Sales will decrease, 
however, at a rate of 8% per annum after the first year. 
17. Sales to Collagenesis will continue for two more years and will match the total square 
footage of other external Homograft sales. 
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TransCyte Proposal Assumptions 
18. Combined internal and external Transcyte sales will increase from 200 cassettes in 
1998 to 750 cassettes in 2003. Within the five-year projection time frame no sales 
will be made to the Detroit Hospital. 
19. Internal sales of Transcyte will plateau at 400 cassettes by the year 2000. 
20. Smith & Nephew will pay for any necessary infrastructure modifications to the 
existing facility. 
21. Transcyte shipping costs, excluding containers, will be paid for by Smith & Nephew. 
22. Allocation of costs is based on the percentage of units sold of either product 
(Homograft or Transcyte) to the total units of tissue (Homograft and Transcyte) sold. 
23. Units of Homograft are measured in square feet, whereas units of Transcyte are 
measured in cassettes. 
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